Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
【発明の名称】グルタメート作用性伝達における異常を処置するための2-アダマンタンメタンアミン化合物
Document Type and Number:
Japanese Patent JP2002535360
Kind Code:
A
Abstract:
The use of a compound of formula (1), as disclosed in the specification, wherein R1, R2, R3, R4, R5 and R6 are independently selected from hydrogen, alkyl and aryl, or pharmaceutically acceptable salts thereof, with the proviso that wherein R1 to R4 and R6 are hydrogen, R5 is not selected from CH2CH2NHSO2CH3, CH2CH2NHSO2CF3 and methyl substituted by SO2NH2, SO3H, PO3H2, CONHOH or a heterocyclic group selected from formulae (a), (b), (c), (d) and (e) in the manufacture of a medicament for use in the treatment of a condition generally associated with abnormalities in glutamatergic transmission.

Inventors:
Gilspie, roger john
Monk, Nathaniel Julius Thomas
Bird, Andrew James
Ward, simon edward
Application Number:
JP2000595674A
Publication Date:
October 22, 2002
Filing Date:
January 26, 2000
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
Bernaris Research Limited
International Classes:
A61K31/13; A61K31/135; A61K31/137; A61K31/381; A61K31/41; A61K31/4245; A61K31/433; A61P1/14; A61P3/10; A61P9/00; A61P9/10; A61P15/06; A61P19/08; A61P25/00; A61P25/02; A61P25/04; A61P25/06; A61P25/08; A61P25/14; A61P25/16; A61P25/18; A61P25/22; A61P25/24; A61P25/28; A61P25/30; A61P25/32; A61P25/36; A61P27/02; A61P27/06; A61P29/00; A61P31/18; A61P31/22; A61P41/00; A61P43/00; C07C211/17; C07C211/27; C07C211/29; C07C215/28; C07C217/60; C07D333/20; (IPC1-7): A61K31/137; A61K31/13; A61K31/381; A61P1/14; A61P3/10; A61P9/00; A61P9/10; A61P15/06; A61P19/08; A61P25/00; A61P25/02; A61P25/04; A61P25/06; A61P25/08; A61P25/14; A61P25/16; A61P25/18; A61P25/22; A61P25/24; A61P25/28; A61P25/30; A61P25/32; A61P25/36; A61P27/02; A61P27/06; A61P29/00; A61P31/18; A61P31/22; A61P41/00; A61P43/00; C07C211/17; C07C211/27; C07C211/29; C07C215/28; C07D333/20
Domestic Patent References:
JPH08501297A1996-02-13
Foreign References:
DE1910560A11969-10-09
DE2521894A11975-12-04
EP0382251A21990-08-16
Other References:
JPN6010032442, Madder A., et al., "Mechanism of esterification of 1,3−dimethylamino alcohols by N−acetylimidazole in acetonitrile and t", Journal of the Chemical Society, Perkin Transactions 2, 1997, No. 12, p. 2787−2793
JPN5002002941, CHAKRABARTI J.K., et al, "Adamantanealkanamines as Potential Antidepressant and Anti−Parkinson Agents", JOURNAL OF MEDICINAL CHEMISTRY, 197406, Vol. 17, No. 6, p. 602−609
JPN6010032444, Kornhuber J., et al., "Effects of the 1−amino−adamantanes at the MK−801−binding site of the NMDA−receptor−gated ion channel", European Journal of Pharmacology: Molecular Pharmacology, 1991, Vol. 206, No. 4, p. 297−300
JPN5002002942, PORTER R.H.P., et al., "Regional Variations in the Pharmacology of NMDA Receptor Channel Blockers: Implications for Therapeu", JOURNAL OF NEUROCHEMISTRY, 1995, Vol. 64, No. 2, p. 614−623
Attorney, Agent or Firm:
Shusaku Yamamoto